Breast Cancer News

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

The effectiveness of trastuzumab in retreating patients with recurrence who received it during perioperative therapy is the focus of a new study.

Do the Risks of Direct-to-Consumer Testing Outweigh the Benefits?

Do the Risks of Direct-to-Consumer Testing Outweigh the Benefits?

There are benefits and drawbacks to the public availability to DTC mutation tests.

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

Understanding various factors associated with unemployment may help to guide breast cancer management to increase the rate of returning to work.

Circulating Tumor Cells Predictive of Adjuvant Radiotherapy Benefit in Early Breast Cancer

Circulating Tumor Cells Predictive of Adjuvant Radiotherapy Benefit in Early Breast Cancer

Researchers determined that there was a significant association between overall survival and adjuvant RT when factoring in CTC status.

Hormone Therapy for Breast Cancer May Cause Diabetes

Hormone Therapy for Breast Cancer May Cause Diabetes

It was unknown whether breast cancer treatment plays a causal role in the onset of diabetes.

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.

Post-Surgery Accelerated Partial Breast Irradiation vs Whole-Breast Irradiation: QoL Outcomes

Post-Surgery Accelerated Partial Breast Irradiation vs Whole-Breast Irradiation: QoL Outcomes

A previous analysis showed that APBI had non-inferior efficacy.

Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer

Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer

At the time of final analysis, 192 of 302 patients had died.

Endocrine Therapy-Associated Alopecia Significantly Affects Quality of Life

Endocrine Therapy-Associated Alopecia Significantly Affects Quality of Life

Improvements in alopecia were, however, seen in 37 of 46 patients treated with topical minoxidil.

Sarcopenia, Adiposity Significantly Associated With Mortality in Nonmetastatic Breast Cancer

Sarcopenia, Adiposity Significantly Associated With Mortality in Nonmetastatic Breast Cancer

Previous studies have demonstrated that sarcopenia, poor muscle quality, and excess adiposity are associated with higher mortality.

Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer

Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer

The median OS was not evaluable, though the estimated 2-year OS rate was 78.7%.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs